Glaucoma is the leading cause of blindness and is often related to high intraocular pressure. However, over 10% have progressive visual loss despite optimal intraocular pressure lowering. Our drugs are proven to reduce visual loss in animal studies. Non-human primate studies are pending, and human trials will begin in 2025.
Diabetic Retinopathy (DR) is caused by damage to blood vessels in the retina of diabetic patients leading to vision loss. Our DR therapeutics are in the early stages of pre-clinical studies
Company Details
- Employees
- 5
- Founded
- 2023
- Address
- 9510 Innovation Lane, La Jolla,ca 92093,united States
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://eyegenex.com/
- Keywords
- Bangalore.
- HQ
- La Jolla, CA
Eyegenex Questions
Eyegenex's website is https://eyegenex.com/
Eyegenex's LinkedIn profile is https://www.linkedin.com/company/eyegenex
Eyegenex has
5 employees.
View email and phone details for 5
employees at Eyegenex.
Eyegenex's industry is
Pharmaceutical Manufacturing
Eyegenex's top competitors are
Eyegene, Inc.,
Aram Experiences Pvt Ltd,
Ginepro Llc,
Ark Medical Solutions Inc.,
Nvi Therapeutics Inc.,
Nervosave Therapeutics,
Lumithera, Inc.,
Rejuvenate Bio,
Mesa,
Opthea.
Eyegenex's categories are Pharmaceutical Manufacturing
Eyegenex's founding year is 2023
